Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206439 · ClinicalTrials.gov registry record · Phase 4
An Advanced Echocardiographic Evaluation of Nebivolol
A Phase 4 study, sponsored by Jack Rubinstein.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT01206439 is a Phase 4 study that was terminated before completion, run by Jack Rubinstein. The registered enrollment target is 2 participants.
The verdict
NCT01206439, a Phase 4 study, was terminated before completion, sponsored by Jack Rubinstein.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Nebivolol has any effect on heart function determined by changes in echocardiographic data or exercise tolerance.
Interventions
- DRUG nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206439
The ClinicalTrials.gov registry entry for NCT01206439 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jack Rubinstein, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nebivolol is the first listed.
NCT01206439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01206439 about?
NCT01206439 is a clinical study titled "An Advanced Echocardiographic Evaluation of Nebivolol". The purpose of this study is to determine if Nebivolol has any effect on heart function determined by changes in echocardiographic data or exercise tolerance.
What is the current status of trial NCT01206439?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2010-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01206439?
The interventions under investigation include: nebivolol (DRUG).
Who is sponsoring clinical trial NCT01206439?
This trial is sponsored by Jack Rubinstein, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.